Mitorx Therapeutics
Develops mitochondrial-targeted small-molecule obesity treatments for people with metabolically unhealthy obesity
Highlights
- New on EvolcAdded 2026-11-07
About Mitorx Therapeutics
MitoRx Therapeutics is developing small-molecule therapies that aim to restore mitochondrial health and treat metabolically unhealthy obesity. Its lead asset, MTRX31, is in preclinical development and is designed to rebalance fat and carbohydrate oxidation.
The company was spun out of the University of Exeter in 2021 and is headquartered in Harwell Oxford, UK, with research operations in Cambridge. Its work focuses on obesity and related cardiometabolic conditions.
Product: Preclinical development of MTRX31, a mitochondrial-targeted small molecule for obesity.
Jobs at Mitorx Therapeutics
Leadership
- Jon Rees · Co-founder & Chief Executive OfficerSource: company website
- Alison Strutt · Chief Financial OfficerSource: company website
- Norman Law · Co-founder, Chief Technology Officer & Head of Intellectual PropertySource: company website
- Stacey Godfrey · VP HR & OperationsSource: company website
More biotech & pharma companies
Modelmole
AI-driven molecular discovery and drug development services for biotechnology and pharmaceutical companiesYoung companyNew on EvolcMoolec Science
Produces animal proteins and plant-based ingredients in crops such as soybean and safflower for food companies worldwideNew on EvolcMoredun Scientific
Contract research and biosafety testing for animal health, aquaculture and biopharmaceutical companiesNew on EvolcMyricx Pharma
Develops antibody-drug conjugate cancer therapies using payloads based on N-myristoyltransferase inhibitorsNew on EvolcNanomerics
Develops polymer-based drug and gene delivery technologies for pharmaceutical therapies in ophthalmology and CNS conditionsNew on EvolcNanosyrinx
Develops targeted intracellular delivery of protein therapeutics for biotech and pharmaceutical drug developersNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- nginxHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.